Securities code: 600671 securities abbreviation: St eye medicine Announcement No.: pro 2022-003 Hangzhou Tianmushan Pharmaceutical Enterprise Co.Ltd(600671)
Suggestive announcement on expiration of shareholders’ agreement on concerted action and termination of the relationship of concerted action
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
Important content tips:
This equity change belongs to the concerted action of Mr. Li Junfeng, Mr. Li Hongxin, Mr. Li Jie and Mr. Zhou Yongzheng, and the agreement on dissolving the person acting in concert is expired.
This equity change does not touch the change in the number of shares, which is the dissolution of the relationship of concerted action by shareholders.
This equity change did not lead to the change of the company’s largest shareholder.
Hangzhou Tianmushan Pharmaceutical Enterprise Co.Ltd(600671) (hereinafter referred to as “the company”) received the notice from the shareholders of the company, Mr. Li Junfeng, Mr. Li Hongxin, Mr. Li Jie and Mr. Zhou Yongzheng, on January 19, 2022. The agreement on concerted action signed by the aforesaid shareholders on January 20, 2021 has expired on January 19, 2022. After consensus, the agreement on concerted action will not be renewed. The relevant information is hereby announced as follows:
1、 Basic information of concerted action relationship
1. The agreement on concerted action signed by Mr. Li Junfeng, Mr. Li Hongxin, Mr. Li Jie and Mr. Zhou Yongzheng on January 20, 2021 (hereinafter referred to as the “agreement on concerted action”) expires on January 19, 2022. The agreement stipulates that from the date of signing the agreement, All parties acting in concert agree to take concerted action when voting on any matter at the general meeting of shareholders of Tianmu pharmaceutical; The agreement is valid for one year.
2. As of the date of this announcement, Li Junfeng holds 3073329 shares, accounting for 2.52% of the total share capital of the company; Li Hongxin holds 2008556 shares, accounting for 1.65% of the total share capital of the company; Li Jie holds 1601923 shares, accounting for 1.31% of the total share capital of the company; Zhou Yongzheng holds 51800 shares, accounting for 0.04% of the total share capital of the company. The four persons hold 6735608 shares of the company, accounting for 5.52% of the total share capital of the company,
2、 Termination of concerted action agreement
Since the agreement on concerted action will expire on January 19, 2022, after friendly negotiation between the parties of the original concerted action, it is decided not to renew the agreement on concerted action after expiration, and the parties of the original concerted action terminate the relationship of concerted action. The original person acting in concert issued the agreement on termination by concerted action, which is as follows:
1. The parties agree that from the effective date of this agreement, the agreement on concerted action jointly signed by the parties on January 20, 2021 will be terminated, and will not be renewed after the parties terminate the relationship of concerted action.
2. The parties agree that from the effective date of this agreement, the parties shall terminate the performance of any rights and obligations agreed under the original concerted action agreement.
3. Each party confirms that during the effective period of the concerted action agreement signed by both parties, each party has complied with the provisions of such agreement without any breach of contract, and each party has no dispute, objection or dispute over the conclusion, performance and termination of such agreement, and each party will not put forward any claim or claim in this regard. 3、 Impact of termination of agreement on concerted action upon the company
1. The shareholders of the company, Mr. Li Junfeng, Mr. Li Hongxin, Mr. Li Jie and Mr. Zhou Yongzheng, will not renew the relationship of concerted action after the expiration of the agreement on concerted action, which is the true intention of the original parties, and does not violate the company law of the people’s Republic of China, the securities law of the people’s Republic of China and the measures for the administration of the acquisition of listed companies The Listing Rules of Shanghai Stock Exchange and other relevant laws, regulations, normative documents and the articles of association do not violate the provisions of the agreement on concerted action, nor do they violate their respective commitments.
2. The above equity changes will not lead to changes in the company’s largest shareholder, have a significant impact on the company’s daily production and operation, and have a significant impact on the company’s main business and financial status.
3. In accordance with the requirements of the securities law of the people’s Republic of China, the measures for the administration of the acquisition of listed companies and other relevant laws and regulations, this equity change report will be prepared as soon as possible and disclosed within the specified time.
The information disclosure media designated by the company are China Securities Journal, securities daily and the website of Shanghai Stock Exchange. The information about the company shall be subject to the information published in the above designated media, so as to draw the attention of investors to investment risks.
4、 Documents for future reference
Termination agreement of persons acting in concert
It is hereby announced.
Board of directors of Hangzhou Tianmu Pharmaceutical Co., Ltd. January 20, 2022
